OMCL 📈 Omnicell - Overview
Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US68213N1090
OMCL: Automation Systems, Dispensing Systems, Robotics, Software, Packaging Supplies
Omnicell, Inc., together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications. It also provides central pharmacy automation solutions; IV compounding robots; and inventory management software. In addition, the company provides single-dose automation solutions that fill and label a variety of patient-specific, single-dose medication blister packaging based on incoming prescriptions; fully automated and semi-automated filling equipment for institutional pharmacies to warrant automated packaging of medications; and medication blister card packaging and packaging supplies to enhance medication adherence in non-acute care settings. Further, it offers EnlivenHealth Patient Engagement, a web-based solutions. The company was formerly known as Omnicell Technologies, Inc. and changed its name to Omnicell, Inc. in 2001. Omnicell, Inc. was incorporated in 1992 and is headquartered in Fort Worth, Texas. Web URL: https://www.omnicell.com
Additional Sources for OMCL Stock
News:
Wall Street Journal
Benzinga
Yahoo Finance
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
OMCL Stock Overview
Market Cap in USD | 2,099m |
Sector | Healthcare |
Industry | Health Information Services |
GiC Sub-Industry | Health Care Technology |
IPO / Inception | 2001-08-07 |
OMCL Stock Ratings
Growth 5y | -41.0% |
Fundamental | -10.2% |
Dividend | - |
Rel. Strength Industry | 261 |
Analysts | 3.78/5 |
Fair Price Momentum | 40.05 USD |
Fair Price DCF | 66.04 USD |
OMCL Dividends
No Dividends PaidOMCL Growth Ratios
Growth Correlation 3m | 50.6% |
Growth Correlation 12m | 65.8% |
Growth Correlation 5y | -65.8% |
CAGR 5y | -11.53% |
CAGR/Mean DD 5y | -0.28 |
Sharpe Ratio 12m | 0.43 |
Alpha | -8.37 |
Beta | 0.86 |
Volatility | 46.64% |
Current Volume | 2644.2k |
Average Volume 20d | 634.2k |
What is the price of OMCL stocks?
As of December 22, 2024, the stock is trading at USD 44.98 with a total of 2,644,184 shares traded.
Over the past week, the price has changed by -2.24%, over one month by +7.56%, over three months by +0.81% and over the past year by +18.59%.
As of December 22, 2024, the stock is trading at USD 44.98 with a total of 2,644,184 shares traded.
Over the past week, the price has changed by -2.24%, over one month by +7.56%, over three months by +0.81% and over the past year by +18.59%.
Is Omnicell a good stock to buy?
Neither. Based on ValueRay Fundamental Analyses, Omnicell is currently (December 2024) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of -10.24 and therefor a neutral outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of OMCL as of December 2024 is 40.05. This means that OMCL is currently overvalued and has a potential downside of -10.96%.
Neither. Based on ValueRay Fundamental Analyses, Omnicell is currently (December 2024) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of -10.24 and therefor a neutral outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of OMCL as of December 2024 is 40.05. This means that OMCL is currently overvalued and has a potential downside of -10.96%.
Is OMCL a buy, sell or hold?
Omnicell has received a consensus analysts rating of 3.78. Therefor, it is recommend to hold OMCL.
Omnicell has received a consensus analysts rating of 3.78. Therefor, it is recommend to hold OMCL.
- Strong Buy: 3
- Buy: 1
- Hold: 5
- Sell: 0
- Strong Sell: 0
What are the forecast for OMCL stock price target?
According to ValueRays Forecast Model, OMCL Omnicell will be worth about 43.4 in December 2025. The stock is currently trading at 44.98. This means that the stock has a potential downside of -3.62%.
According to ValueRays Forecast Model, OMCL Omnicell will be worth about 43.4 in December 2025. The stock is currently trading at 44.98. This means that the stock has a potential downside of -3.62%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | 56.6 | 25.8% |
Analysts Target Price | 66.4 | 47.7% |
ValueRay Target Price | 43.4 | -3.6% |